Demonstrates enhanced 1,3-butanediol production in E. coli through engineering of butyraldehyde dehydrogenase, suggesting new targets for enzyme modification.
Microbial production of 1,3-butanediol (1,3-BDO) offers a renewable route to this versatile C₄ chemical. However, the low performance of CoA-acylating butyraldehyde dehydrogenase (Bld), which contains a catalytic cysteine, limits efficient production in recombinant Escherichia coli (E. coli). In this study, wild-type Clostridium saccharoperbutylacetonicum Bld and its variant Bld* were biochemically characterized and engineered to improve conversion of 3-hydroxybutyryl-CoA (3-HB-CoA) to 3-hydroxybutyraldehyde (3-HBA). Enzyme activity was strongly reduced by the product, 3-HBA, and this reduction was largely alleviated by added cysteine. To mitigate this interference, several noncatalytic cysteine residues in Bld* were substituted individually and in combination guided by multiple sequence alignment and machine-learning-based mutational prediction. The triple mutant C151N/C189A/C353L (designated CYS31) displayed ~30% higher specific activity without altering substrate affinity or selectivity. Incorporation of CYS31 into a 1,3-BDO-producing E. coli strain led to a corresponding ~30% increase in titer, indicating that enhanced in vitro kinetics translated to higher in vivo 1,3-BDO production. These findings provide a more effective Bld variant for 1,3-BDO production and demonstrate that non-active-site cysteine residues can be viable engineering targets when an aldehyde intermediate is involved.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: